- Home
- INOD vs CTNM Comparison
INOD vs CTNM Comparison
Compare INOD & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INOD
- CTNM
- Stock Information
- Founded
- INOD 1988
- CTNM 2009
- Country
- INOD United States
- CTNM United States
- Employees
- INOD N/A
- CTNM N/A
- Industry
- INOD EDP Services
- CTNM
- Sector
- INOD Technology
- CTNM
- Exchange
- INOD Nasdaq
- CTNM Nasdaq
- Market Cap
- INOD 1.2B
- CTNM 377.6M
- IPO Year
- INOD 1993
- CTNM 2024
- Fundamental
- Price
- INOD $33.95
- CTNM $12.77
- Analyst Decision
- INOD Strong Buy
- CTNM Strong Buy
- Analyst Count
- INOD 4
- CTNM 4
- Target Price
- INOD $36.50
- CTNM $29.25
- AVG Volume (30 Days)
- INOD 1.7M
- CTNM 148.5K
- Earning Date
- INOD 02-20-2025
- CTNM 02-16-2025
- Dividend Yield
- INOD N/A
- CTNM N/A
- EPS Growth
- INOD N/A
- CTNM N/A
- EPS
- INOD 0.62
- CTNM N/A
- Revenue
- INOD $137,393,000.00
- CTNM N/A
- Revenue This Year
- INOD $93.11
- CTNM N/A
- Revenue Next Year
- INOD $34.30
- CTNM N/A
- P/E Ratio
- INOD $54.63
- CTNM N/A
- Revenue Growth
- INOD 71.66
- CTNM N/A
- 52 Week Low
- INOD $5.46
- CTNM $12.33
- 52 Week High
- INOD $55.17
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- INOD 40.92
- CTNM N/A
- Support Level
- INOD $32.54
- CTNM N/A
- Resistance Level
- INOD $46.69
- CTNM N/A
- Average True Range (ATR)
- INOD 3.43
- CTNM 0.00
- MACD
- INOD -1.22
- CTNM 0.00
- Stochastic Oscillator
- INOD 9.96
- CTNM 0.00
About INOD Innodata Inc.
Innodata Inc is a digital services and solutions company. It provides technology and services to information products and online retail destinations. The company has three operating segments: Digital data solutions, Synodex, and Agility. It serves publishers, media and information companies, digital retailers, banks, insurance companies, government agencies, and other industries. Geographically, it operates in the United States, United Kingdom, Netherlands, Canada, and Europe.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.